Polygenic Risk Score Improves the Accuracy of a Clinical Risk Score for Coronary Artery Disease

- 2 Mustin King¹, Lang Wu², Hong-Wen Deng³, Hui Shen³, Chong Wu¹
-
-
- 1. Department of Statistics, Florida State University, Tallahassee, FL, USA
- 2. Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI, USA
- 3. Center of Bioinformatics and Genomics, Department of Global Biostatistics and Data Science, Tulane University, New Orleans, LA, USA
- **Abstract**
-
- **Background:** The value of polygenic risk scores (PRS) towards improving guideline-recommended clinical
- risk models for coronary artery disease (CAD) prediction is controversial. Here we examine whether an
- integrated polygenic risk score improves prediction of CAD beyond pooled cohort equations.
- **Methods:** An observation study of 291,305 unrelated White British UK Biobank participants enrolled
- from 2006 to 2010 was conducted. A case-control sample of 9,499 prevalent CAD cases and an equal
- number of randomly selected controls was used for tuning and integrating of the polygenic risk scores. A
- separate cohort of 272,307 individuals (with follow-up to 2020) was used to examine the risk prediction
- performance of pooled cohort equations, integrated polygenic risk score, and PRS-enhanced pooled co-
- hort equation for incident CAD cases. Performance of each model was analyzed by discrimination and
- 20 risk reclassification using a 7.5% threshold.
- **Results:** In the cohort of 272,307 individuals (mean age, 56.7 years) used to analyze predictive accuracy,
- there were 7,036 incident CAD cases over a 12-year follow-up period. Model discrimination was tested
- 23 for integrated polygenic risk score, pooled cohort equation, and PRS-enhanced pooled cohort equation
- with reported C-statistics of 0.640 (95% CI, 0.634-0.646), 0.718 (95% CI, 0.713-0.723), and 0.753 (95% CI,
- 0.748-0.758), respectively. Risk reclassification for the addition of the integrated polygenic risk score to
- the pooled cohort equation at a 7.5% risk threshold resulted in a net reclassification improvement of

- 0.117 (95% CI, 0.102 to 0.129) for cases and -0.023 (95% CI, -0.025 to -0.022) for noncases [overall:
- 0.093 (95% CI, 0.08 to 0.104)]. For incident CAD cases, this represented 14.2% correctly reclassified to
- the higher-risk category and 2.6% incorrectly reclassified to the lower-risk category.
- **Conclusions and Relevance:** Addition of the integrated polygenic risk score for CAD to the pooled cohort
- questions improves the predictive accuracy for incident CAD and clinical risk classification in the White
- 32 British from the UK biobank. These findings suggest that an integrated polygenic risk score may enhance
- CAD risk prediction and screening in the White British population.
-

Background

 Cardiovascular disease (CVD) is a major cause of death worldwide.¹ Risk estimates for CVD have 37 become particularly important for disease prevention and clinical practice.^{2,3,4,5} Current guidelines from the American College of Cardiology and American Heart Association suggest lipid-lowering treatments for individuals with greater than a 7.5% 10-year absolute risk of developing CVD based on pooled cohort 40 equations (PCE).⁶ Because of the central role of accurate risk estimates in CVD prevention, improving ac- curacy beyond those already used in clinical practice like PCE, could save lives by better identifying high risk individuals.

 Substantial advancements have been made over the past decades in identifying genetic variants 44 associated with coronary artery disease (CAD).^{7,8,9,10} Recent advances in polygenic risk scores (PRSs) have sparked a great interest in enhancing disease risk prediction by using the information on millions of vari-46 ants across the genome.^{11,12,13,14} However, population health utility of PRSs in CAD risk prediction is con- troversial. Several studies have shown that PRSs can improve risk prediction accuracy for incident and 48 prevalent CAD cases compared with individual conventional risk factors^{15,16} and combing risk prediction 49 models (like PCE) with PRS improves the performance in terms of net reclassification improvement.¹⁷ On 50 the other hand, several studies^{18,19} integrating PRSs into PCE to assess possible clinical utility have con- cluded that the current benefits of incorporating PRSs were minimal (although statistically significant) and were not considered clinically significant to warrant their use over current clinical used prediction models. In this manuscript, we investigate why different studies have reached different and controver- sial conclusions. Specifically, we analyzed UK Biobank data to test the hypothesis that integrated PRSs leveraging multiple newly developed PRS methods, and several genome-wide association study (GWAS) datasets, can improve risk prediction for CAD over the widely used PCE and thus provide improved clini-57 cal utility in European populations.^{9,20,21,22,23,24,25} Furthermore, in secondary analysis, we extended our integrated method to analyze its predictive performance in non-European populations.

Methods

Study Populations

ancestries as: AFR over EUR, SAS over EUR, and EUR over EAS. Participants were excluded if no likeli-

- hood was > 0.3 or if 3 ancestry groups were > 0.3 (n = 8). The same quality control used in primary analy-
- 84 sis was then applied to the resulting AFR ancestry population.
- The study population was divided into (1) a case-control study (tuning dataset) established from
- prevalent CAD cases (see Cardiovascular Outcome Definitions Subsection for details) and randomly se-
- lected controls and (2) an independent prospective cohort study (testing dataset) of participants with no
- 88 history of CAD at baseline recruitment. The tuning dataset was used for building risk prediction models
- and the testing dataset was used for unbiasedly evaluating their performance. Of note, there were no
- overlapping participants between these two datasets, ensuring the testing results were valid.

Definition of Risk Score Variables

- The updated pooled cohort equation (PCE) model, a clinically used risk prediction model, was used as our baseline. We matched variables available in the cohort to the predictors of the updated 94 PCE,³ including information on age, sex, race and ethnicity, smoking status, total and HDL cholesterol, systolic blood pressure, diabetes, and the use of lipid lowering and blood pressure lowering medica- tions. Definitions for Type 1 and Type 2 diabetes, blood pressure lowering and lipid lowering medica- tions use as well as categorization of smoking status were defined based on UK-recommended QRISK3 98 scores.^{31,32} Details of variable definitions and protocol for handling missing values are relegated to the eMethods section of Supplementary. **Figure 1. Study Design and Flowchart for Coronary Artery Disease (CAD)**
- 101 A. Selection of PRS in case-control study
-
- B. Cohort Study
-
-

Cardiovascular Outcome Definitions

122 Information on genotyping and imputation has been described in detail elsewhere.^{27,33} Standard quality-control procedures were applied to the imputed UK Biobank genotype data. Briefly, we re-124 stricted our analyses to autosomal genetic variants, kept variants with imputation information score 125 (INFO) score > 0.3, minor allele frequency > 1%, Hardy-Weinberg equilibrium P > 10^{-10} , and genotype missing rate < 10%. We further removed variants with ambiguous strands (A/T or C/G).

127 PRS for CAD were derived as weighted sums of risk alleles using 3 CAD GWAS datasets (CARDIo-GRAMplusC4D, FinnGen Biobank, Japan Biobank) that had no overlap with the present UK Biobank study

7

(**Figure 1**).8,9,25 129 The 3 GWAS datasets were filtered to only include SNPs present in the imputed UK Bi- obank data. For all datasets, we aligned β and allele frequencies to the hg19 alternate allele. First, we performed a fixed-effect meta-analysis focused on GWAS datasets with subjects of European ancestry, 132 specifically the CARDIoGRAMplusC4D and FinnGen datasets, using METAL.³⁴ Second, the PRSs were cal- culated by using either Japan Biobank data or combined European data and their corresponding popula-tion-specific 1000 Genome Project constructed LD reference panels.

135 Tuning of the PRS was implemented using seven methods: (1) clumping and thresholding using 136 PRSice-2 software (version 2.3.3),³⁵ (2) LDpred,²⁰ (3) lassosum,³⁶ (4) PRS-CS,²¹ (5) sBayesR,²² (6) LDpred-137 funct,²³ and (7) DBSLMM.²⁴ Detailed information on each PRS method and their associated parameters 138 are described in the eMethods section of Supplementary. All methods utilized were adjusted for geno-139 type measurement batch and the first five genetic principal components calculated by the UK Biobank. 140 Since different PRS methods and datasets may capture different information, we constructed the inte-141 grated PRS by $\sum_{j=1}^q \hat{\beta}_j PRS_j$, where $\hat{\beta}_j$ is the estimated coefficient of PRS_j in the logistic regression using 142 the tuning dataset and PRS_j is the jth PRS.³⁷ Selection of PRS methods for the integrated model was de-143 termined based on are under the curve (AUC) results from the tuning dataset. Methods with the largest 144 AUC improvement over the PCE model were selected and analyzed in the testing dataset until the inclu-145 sion of additional PRS methods failed to improve the predictive performance of the integrated model. 146 We assessed the performance of the integrated model against the individual PRS methods in the testing 147 dataset as well as models combining the European meta-analysis data and Japan Biobank data.

148 **Statistical Analysis**

149 Participants were excluded from the study for multiple factors, including missing genetic data, 150 mismatches in reported and genotypic sex, withdrawal of informed consent, and missing predictor val-151 ues. Using previously published baseline coefficients for each predictor variable and baseline hazard, we

8

167 threshold of 7.5% (clinically used in the United States), continuous NRI, and associated integrated dis-

168 crimination improvement (IDI).⁴³ These metrics quantify how well a new model (PCE plus PRS) reclassi-

169 fies individuals compared to an old model (PCE); a brief explanation of these metrics can be found in the 170 eMethods section of the Supplementary.

171 Statistical analyses were conducted in R software, version 4.0.0 (R Project for Statistical Compu-172 ting).⁴⁴ Anaconda, version 3.8.3, was also used for PRS methods that utilized Python programming lan- 173 guage. 45

174 **Results**

224 by fitting predicted log-HRs as covariates in the model, resulting in considerable improvement in model 225 calibration (Supplementary Figure 2).

to the high-risk category (**Figure 4B**).

247 When comparing integrated PRS for CAD model to the PCE model, the NRI for cases was 11.7%

 We found that integrating PRS to baseline PCE model resulted in significant continuous and cat- egorical NRI. Categorical NRI for incident cases was 11.7% and -2.3% for noncases. Our model greatly 298 improved reclassification for cases over previous studies, $17,18,19$ but resulted in more misclassification in non-case individuals. This difference in performance for noncases may be due in part to model specifica- tions and cohort selection. In contrast to Moseley et al,¹⁹ in which the 2013 PCE model was used, we uti-301 lized the updated 2018 PCE as our baseline. The 2013 model was noted to overestimate risk across all 302 risk groups, prompting the development of the updated PCE model.³ We also used a younger cohort compared to the two cohorts in Moseley et al (mean age 56.7 years compared to 62.9 and 61.8, respec- tively). As noted, we included only White British ancestry in our primary cohort. The inclusion of other ethnicities in the cohort may significantly decrease the discrimination power of the PRS constructed. This is shown in our secondary analysis of African ancestry, where the PRS results based on a European ancestry GWAS dataset vastly underperformed compared to the White British population (C-statistics 0.715 vs 0.752, respectively) (Supplementary Table 5). Our results suggest an association between predictive accuracy of PRS and incident CAD events

 that varies based on age and sex. Men showed significantly higher C-statistic improvement than women (0.051 vs 0.035) in the PRS-enhanced PCE model over the baseline PCE model. This is complemented by an 11.6% overall categorical NRI improvement in men compared to 3.6% in women (Supplementary Ta- ble 6). Recent studies using PRS in the UK Biobank demonstrated comparable results with higher risks for incident CAD in men than women.^{15,47,50} The improved performance in men may be attributed to overrepresentation of male CAD cases in the case-control and cohort studies. The use of sex-specific data may lead to improved prediction accuracy of PRS.

 Our results also suggest a genetic component to early-onset cases of CAD and a possible applica- tion of PRS in identifying individuals at heightened risk of these cases, as the predictive accuracy of inci-dent CAD cases was higher in participants < 55 years of age. The observed C-statistic for the integrated

15

320 PRS-enhanced PCE model was 0.793 compared to 0.705 observed in the ≥ 55 age group. This observa-321 tion supports two recent studies that found high risk score predictions in genetic variants strongly asso-322 ciated with early-onset CAD (<40 years old) as well as improved risk classification of early-onset CAD to 323 higher-risk categories that were not classified as such by PCE. $9,51$

 There are limitations in our study. First, our study was conducted in the UK Biobank and is, therefore, limited by the characteristics of the cohort. The UK Biobank cohort is composed of primarily European ancestries (further restricted to White British ancestry in this study) and limited to an age 327 range of 40 to 69 years, restricting its application to other ancestries and age groups. In addition, partici- pants in the UK Biobank assessment tend to be healthier and more well-off compared to the general UK 329 population,⁵² and thus population-level CAD risk may be underestimated in our study. In secondary anal- ysis, the limited genetic diversity of the UK Biobank cohort is apparent and resulted in significantly smaller tuning and testing. The extent to which our results can be applied to larger non-European ances- tries, in particular African ancestry, warrants further investigation. These results also highlight the ur-333 gency of developing novel cross-ancestry PRS methods^{10,17,53,54,55} and using more diverse cohorts to con-334 struct PRSs.¹⁷ In addition, as the case-control and cohort analyses are derived from the same study, more broad generalizability of the results requires further investigation. Second, this study included PRS 336 for low frequency and common genetic variants (MAF \geq 1%) and did not examine the predictive accu- racy of rare variants known to affect CAD risk. Third, the algorithm for selection of CAD cases utilizes self-report, death, and hospital inpatient data for the definition of prevalent and incident CAD cases. As such, misclassification of cases is possible. Fourth, tuning of each PRS method in the case-control study used prevalent CAD cases, which could introduce survival bias. However, simulation studies have demonstrated a limited effect of survival bias on estimated genetic effects of event risks.⁵⁶ Fifth, partici-342 pants with at least 1 missing predictor value were excluded from the study. Excluded participants were

- not considerably different demographically from those included and thus the missing data are unlikely
- to have a significant effect on the reported estimates.

Conclusions

- 346 Addition of the integrated CAD PRS to the PCE resulted in a statistically significant improvement
- in predictive accuracy for incident CAD, especially in individuals under the age of 55 years old in White
- British population. It was also associated with moderate improvement in risk reclassification across all
- subgroups. However, the benefits of adding integrated CAD PRS to the PCE are minimal for African pop-
- ulation. In summary, the inclusion of genetic information to the pooled cohort equation can help im-
- prove clinical risk classification and demonstrates the potential for genetic screening in early life to im-
- prove clinical risk prediction in White British population.
-
-

Abbreviations

- Cardiovascular disease (CVD); pooled cohort equations (PCE); coronary artery disease (CAD); polygenic
- risk score (PRS); genome-wide association study (GWAS); African (AFR); East Asian (EAS); European
- (EUR); South Asian (SAS); hospital episode statistics (HES); area under the curve (AUC); net reclassifica-
- tion improvement (NRI); integrated discrimination improvement (IDI); confidence interval (CI)

References

- 1. GBD 20019 Disease and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet*. 2020; 396(10258):1204-1222.
- 2. Damen JA, Hooft L, Schuit E, et al. Prediction models for cardiovascular disease risk in the general population: systematic review. *BMJ*. 2016;353:i2416.

- 20. Vilhjálmsson B, Yang J, Finucane H, et al. Modeling Linkage Disequilibrium Increases Accuracy of Pol-ygenic Risk Scores. *American Journal of Human Genetics*. 2015;97(4):576-592.
- 21. Ge T, Chen C, Ni Y, et al. Polygenic prediction via Bayesian regression and continuous shrinkage pri-ors. *Nature Communications*. 2019;10(1).
- 22. Lloyd-Jones L, Zeng J, Sidorenko J, et al. Improved polygenic prediction by Bayesian multiple regres-sion on summary statistics. *Nature Communications*. 2019;10(1).
- 23. Márquez-Luna C, Gazal S, Loh P, et al. LDpred-funct: incorporating functional priors improves poly-genic prediction accuracy in UK Biobank and 23andMe data sets. *bioRxiv*. 2018;375337.
- 24. Yang S, Zhou X. Accurate and Scalable Construction of Polygenic Scores in Large Biobank Data Sets. *American Journal of Human Genetics*. 2020;106(5):679-693.
- 25. Nagai A, Hirata M, Kamatani Y, et al. Overview of the BioBank Japan Project: Study design and pro-file. *Journal of Epidemiology*. 2017;27(3):S2-S8.
- 26. Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med*. 2015;12(3):e1001779.
- 27. UK Biobank. Biomarker assay quality procedures: approaches used to minimize systematic and ran- dom errors (and the wider epidemiological implications): version 1.2. *https://biobank.ctsu.ox.ac.uk/crys-tal/cyrstal/docs/biomarker_issues.pdf*. Published April 2, 2019. Accessed August 10, 2021.
- 420 28. Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep phenotyping and ge-nomic data. *Nature*. 2108;562(7726):203-209.
- 422 29. Wang Y, Guo J, Ni G, et al. Theoretical and empirical quantification of the accuracy of polygenic scores in ancestry divergent populations. *Nature Communications*. 2020;11:3865.
- 424 30. Backman J, Li A, Marcketta A, et al. Exome sequencing and analysis of 454,787 UK Biobank partici-pants. *Nature*. 2021;599:628-634.
- 426 31. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. *BMJ*. 2008;336(7659):1475-1482.
- 428 32. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algo-rithms to estimate future risk of cardiovascular disease: prospective cohort study. *BMJ*. 2017;357:j2099.
- 430 33. UK Biobank. Genotype imputation and genetic association studies of UK Biobank: interim data re- lease. *http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/imputation_documentation_May2015.pdf*. Published May 2015. Accessed January 10, 2019.
- 34. Willer C, Li Y, Abecasis G. METAL: Fast and efficient meta-analysis of genome wide association scans. *Bioinformatics*. 2010;26(17):2190-2191.
- 35. Choi S, Mak T, O'Reilly P. Tutorial: a guide to performing polygenic risk score analyses. *Nature Proto-cols*. 2020;15(9):2759-2772.
- 36. Mak T, Porsch R, Choi S, et al. Polygenic scores via penalized regression on summary statistics. *Ge-netic Epidemiology*. 2017;41(6):469-480.

439 37. Wu C, Zhu J, King A, et al. Novel strategy for disease risk prediction incorporating predicted gene ex- pression and DNA methylation data: a multi-phased study of prostate cancer. *Cancer Communications*. 2021;41(12):1387-1397.

- 38. SOMERSD. Stata module to calculate Kendall's tau-a, Somers' D. and median differences [computer program]. Version S336401: Boston College Department of Economics; 1998.
- 39. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluation the yield of medical tests. *JAMA*. 1982;247(18):2543-2546.
- 40. Newson R. Parameters behind "nonparametric" statistics: Kendall's tau, Somers' D and median dif-ferences. *Stata J*. 2002;2(1):45-64.
- 41. Demler O, Paynter N, Cook N. Tests of calibration and goodness-of-fit in the survival setting. *Statis-tics in Medicine*. 2015;34(10):1659-1980.
- 42. Leening M, Vedder M, Witteman J, et al. Net Reclassification Improvement: Computation, Interpre-tation, and Controversies A Literature Review and Clinician's Guide. *Ann Intern Med*. 2014;160:122-131.
- 43. Pencina MJ, Steyerberg EW, D'Agostino RB Sr. Net reclassification index at event rate: properties and relationships. *Stat Med*. 2017;36(28):4455-4467.
- 44. The R Project for Statistical Computing [computer Program]. Version 4.0.0, Vienna, Austria: 2013.
- 45. Anaconda Software Distribution [Internet]. Anaconda Documentation. Anaconda Inc.; 2020. Availa-ble from: https:/docs.anaconda.com/
- 46. Aragam K, Dobbyn A, Judy R. et al. Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. *J Am Coll Cardiol*. 2020;75(22):2769-2780.
- 47. Riveros-McKay F, Weale M, Moore R, et al. Integrated Polygenic Tool Substantially Enhances Coro-nary Artery Disease Prediction. *Circulation: Genomic and Precision Medicine*. 2021; 14(2):e003304.
- 48. Gola D, Erdmann J, Läll K, et al. Population Bias in Polygenic Risk Prediction Models for Coronary Ar-tery Disease. *Circulation: Genomic and Precision Medicine*. 2020;13(6):e002932.
- 49. Matsunaga H, Ito K, Akiyama M, et al. Transethnic Meta-Analysis of Genome-Wide Association Stud- ies Identifies Three New Loci and Characterizes Population-Specific Differences for Coronary Artery Dis-ease. *Circulation: Genomic and Precision Medicine*. 2020;13(3):e002670.
- 50. Manikpurage H, Eslami A, Perrot N, et al. Polygenic Risk Score for Coronary Artery Disease Improves the Prediction of Early-Onset Myocardial Infarction and Mortality in Men. *Circulation: Genomic and Preci-sion Medicine*. 2021;14(6):e003452.
- 51. Thériault S, Lali R, Chong M, et al. Polygenic Contribution in Individuals With Early-Onset Coronary Artery Disease. *Circulation: Genomic and Precision Medicine*. 2018;11(1).
- 52. Fry A, Littlejohns T, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Character- istics of UK Biobank Participants with Those fo the General Population. *American Journal of Epidemiology*. 2017;186(9):1026-1034.
- 53. Fritsche L, Ma Y, Zhang D, et al. On cross-ancestry cancer polygenic risk scores. *PLoS Genet*. 2021;17(9):e1009670.

- 476 54. Chen C, Han J, Hunter D, Kraft P, Price A. Explicit Modeling of Ancestry Improves Polygenic Risk Scores and BLUP Prediciton. *Genetic Epidemiology*. 2015;39(6):427-438.
- 55. Cai M, Xiao J, Zhang S, et al. A unified framework for cross-population trait prediction by leveraging the genetic correlation of polygenic traits. *AJHG*. 2021;108(4):632-655.
- 56. Hu YJ, Schmidt AF, Dudbridge F, et al; The GENIUS-CHD Consortium. Impact of selection bias on esti-
- mation of subsequent event risk. *Circ Cardiovasc Genet*. 2017;10(5):e001616.
-

21

483 **Figure 1. Study Design and Flowchart for Coronary Artery Disease (CAD)**

484 A. Selection of PRS in case-control study

485

486 B. Cohort Study

487

- 488
489
-

 $\frac{490}{490}$ To select the parameters for each method with the best discrimination based on area under the curve (AUC), clumping and thresholding,
 491 LDpred, lassosum, PRS-CS, sBayesR, LDpred-funct, and DBSLMM were us $491\pm$ LDpred, lassosum, PRS-CS, sBayesR, LDpred-funct, and DBSLMM were used to calculate polygenic risk scores (PRS) on the case-control set con-
 $492\pm$ sisting of prevalent cases. For these calculations, summary data fo 492 sisting of prevalent cases. For these calculations, summary data for three genome-wide association studies (GWAS) on CAD (CARDIoGRAM-
493 olusC4D, Finngen Biobank, Japan Biobank) that excluded UK Biobank and data on li 493 plusC4D, Finngen Biobank, Japan Biobank) that excluded UK Biobank and data on linkage disequilibrium were used. The calculated PRS were
494 applied to a nonoverlapping set of participants from the UK Biobank with no pr 494 applied to a nonoverlapping set of participants from the UK Biobank with no preexisting CAD, aged 40 to 69 at baseline, and who were followed
495 up for incident CAD events. In this population, the pooled cohort equati

 495 up for incident CAD events. In this population, the pooled cohort equations (PCE) model was calculated and different models (PRS, PCE, PRS-
 496 enhanced PCE) were compared in terms of their predictive accuracy bas enhanced PCE) were compared in terms of their predictive accuracy based on discrimination, calibration, and reclassification metrics.

22

498 **Table 1. C-Statistics for Coronary Artery Disease for Full Population and Stratified by Sex and Age**

Group (Younger and Older than 55 Years of Age) 1,2 499

504

505

506

Figure 2. Receiver Operator Characteristic Curves and C-Statistics for Different Models in Cohort Analyses of White British and African Ancestry Populations

 PCE indicates pooled cohort equation; PRS indicates integrated polygenic risk score. A) is the White British population of 272,307 individuals
over a mean 12 years of follow-up with 7036 incident CAD cases and B) is over ^a mean ¹² years of follow-up with ⁷⁰³⁶ incident CAD cases and B) is the African ancestry population of 6,753 individuals over ^a mean ¹³

years of follow-up with 88 incident CAD cases.

Figure 3. Cumulative Absolute Risk of Developing CAD

Cumulative absolute risk of developing CAD by quintiles of the overall polygenic score in **A)** the PCE model and **B)** the PRS-en-

hanced PCE model. The shaded portions correspond to the 95% confidence interval.

523 **Figure 4. Change in Predicted Probabilities and Risk Reclassification**

524 A. Difference between 10-y risk by PCE and PRS-enhanced PCE

526

527 B. PCE + PRS 10-year risk reclassification

528

529

530

531

532

534 C. Net reclassification improvement and integrated discrimination improvement results

	No. of Participants	Continuous Net Reclassification Improvement	Categorical Net Reclassification Improvement	Integrated Discrimination Improvement
Cases	7036	0.215 (0.194 to 0.228	$0.117(0.102 \text{ to } 0.129)$	
Noncases	256072	$0.235(0.224 \text{ to } 0.25)$	-0.023 (-0.025 to - 0.022)	
Full Population	263108	0.45 (0.423 to 0.478)	0.093 (0.08 to 0.104)	0.0564 (0.0534 to 0.0594)
Censored	9230			

535
536
537
538
539 A, Change in the predicted probabilities of the recalibrated pooled cohort equations (PCE) model after the addition of polygenic risk scores 537 (PRS) for CAD. The x-axis shows the predicted probability from the baseline PCE model. The y-axis is the difference in 10-year risk probabilities of a CAD event between the PRS-enhanced model and the baseline PCE model. The scatterplot has a random draw of 1% of the participants 539 shown. The histogram x- and y-axes are based on the full population. B, Reclassification table of predicted probabilities by PCE and PRS-en-
hanced PCE models at 7.5% threshold. Rows indicating an improved classificati hanced PCE models at 7.5% threshold. Rows indicating an improved classification with the PRS-enhanced PCE model are marked by a plus sign while rows indicating a deteriorated classification are marked by a minus sign. C, Table of net reclassification improvement (NRI) and integrated 542 discrimination improvement (IDI). NRIª is defined in the continuous case as the sum of proportions of cases and noncases with improved com-
 543 bined score minus the sum of proportions with deteriorated combined s $543\quad$ bined score minus the sum of proportions with deteriorated combined score. In the categorical case, NRI is defined by changed at a 7.5%
 $544\quad$ threshold predicted probability. A positive NRI indicates a better co 544 threshold predicted probability. A positive NRI indicates a better combined score overall. IDI^b measures the difference of average probabilities
 545 of an event in cases and noncases. A larger IDI indicates more of an event in cases and noncases. A larger IDI indicates more discrimination in the combined score.

 546 \blacksquare ^a NRI = P(up|case) - P(down|case) - P(up|noncase) + P(down|noncase) ^b IDI = P_{PCE+PRS}(case) - P_{PCE+PRS}(noncase) - P_{PCE}(case) + P_{PCE}(noncase)